Co-founder and executive chair of the board of directors of
EIP Pharma, Inc.
Member of the board of directors of
Revvity Inc. and F2G Ltd.
Advisor to Sofinnova Telethon
Fund.
President of Human Genetic Therapies Shire PLC, 2007-2013.
Executive chair of IDM Pharma Inc., 2006-2007.
President and chief executive officer in GlycoFi Inc.,
2003-2004.
Considered independent under the Danish Corporate Governance
Recommendations.
Member of the Board of Directors since March
2015. Most recently elected in 2023 for a term of one year.
Member of the Audit Committee since March 2015. The Board has
assessed that Ms Grégoire qualifies as independent pursuant to the
US Securities Exchange Act.
Member of the Research &
Development Committee since March 2017.
Member of the
Nomination Committee since March 2018.
Global corporate leadership.
Healthcare and pharma
industry.
Medicine & science.
Finance &
accounting.
Business development, M&A and external
innovation sourcing.
Human capital management.
1986: Pharmacy Doctorate degree, the State University of NY at
Buffalo, US,
1984: BA in Pharmacy, Laval University,
Canada.
1980: Science College degree, Séminaire de
Sherbrooke, Canada.